Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction
Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction
复制标题
结合珠蛋白基因型在治疗 HDL 功能障碍中的药物基因组学应用
DOI:
--
复制
发表时间:
2009
影响因子:
1.9
通讯作者:
A. Levy
中科院分区:
文献类型:
--
作者:
Avery Schwartz;S. Blum;R. Asleh;M. Pollak;Shiri Kalet;A. Levy
An emerging paradigm of research has suggested that in the setting of diabetes mellitus (DM) the quality or function of high-density lipoprotein (HDL) may be a determinant of cardiovascular disease risk. Specific structural modifications of HDL protein and lipid components, resulting from oxidative modification, have been proposed to mediate HDL’s loss of the ability to promote cholesterol efflux (reverse cholesterol transport), serve as an antioxidant and anti-inflammatory agent. Therefore, inhibiting HDL oxidative modification would be expected to improve its function and provide cardioprotection. Nevertheless, antioxidant strategies to reduce cardiovascular events from atherosclerosis in DM have failed. It has been proposed that this failure may have been due to the inadequate nature of patient selection. High dose antioxidant therapy may only provide benefit to a subset of DM individuals with oxidatively modified HDL. We will review evidence that haptoglobin (Hp) identifies such individuals who can be successfully treated with vitamin E. These data will suggest that a pharmacogenomic approach utilizing the Hp genotype may be useful in identifying individuals who will benefit from antioxidant therapy.
登录
查看更多内容
影响因子:
2.1
作者:
Blum S;Vardi M;Brown JB;Russell A;Milman U;Shapira C;Levy NS;Miller-Lotan R;Asleh R;Levy AP
通讯作者:
Levy AP
影响因子:
15.9
作者:
Vaisar, Tomas;Pennathur, Subramaniam;Heinecke, Jay W.
通讯作者:
Heinecke, Jay W.
DOI:
10.1016/s0735-1097(02)02534-2
发表时间:
2002-12-04
影响因子:
24
作者:
Levy, AP;Hochberg, I;Howard, BV
通讯作者:
Howard, BV
影响因子:
16.2
作者:
Roguin, A;Koch, W;Levy, AP
通讯作者:
Levy, AP
影响因子:
20.3
作者:
Melamed-Frank, M;Lache, O;Levy, AP
通讯作者:
Levy, AP